- Low
- 54,269
- Average
- 79,750
- Median
- 71,907
- High
- 270,000
Immunogen Salary
39
57
28
| Job Title | Salaries | City | Year | More info |
| Senior Medical Director | 270,000-270,000 | Waltham, MA, 02154 | 2013 | Immunogen Senior Medical Director Salaries (1) Immunogen Waltham, MA Salaries |
| Research Associate Ii | 58,000-58,000 | Waltham, MA, 02154 | 2012 | Immunogen Research Associate Ii Salaries (1) Immunogen Waltham, MA Salaries |
Related Immunogen Salary
- CVS Salary
- Mayo Clinic Salary
- Cerner Salary
- Medtronic Salary
- Amgen Salary
- Asian Counseling And Referral Service Salary
- Friendly Franchisees Salary
- Asse International Salary
- Trc Engineers Salary
- Louisiana Department Of Health And Hospitals Salary
- Baker Botts Salary
- T3 Energy Services Salary
- Cenzic Salary
- Siemens It Solutions And Services Salary
Calculate how much you could earn
It's FREE. Based on your input and our analysis. How we do it?
All fields are required for calculation accuracy.
- We will send you an email to access your personalized report.
- We won’t share your email address
Real Jobs Salary - Salary List- 8.5 million company & government reported salaries with date & location
- Salary calculator rank & calculate your salary
- 151 million W-2s pay scale statistics in U.S.
- Salary Map helps you navigate location based salary information
- State & City Salary provides wage data by metropolitan areas
- Company Salaries has salaries data from over 200,000 companies
Guyp Salary Immunogen Jobs
| See more Immunogen Jobs» | |
| Search All Jobs | |
Patents information
3286
All Patents
809
Grant Patents
2003
Patents Pending
547
Patents Families
More Recent
Immunogen... Information
- ImmunoGen, Inc.
- Industry: BioTech/Drugs
- City: Waltham, MA
- ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company has extensive expertise and intellectual property related to identification of biological targets for cancer treatments, development and humanization of monoclonal antibodies, and creation of potent cell-killing agents designed for antibody delivery to cancer cells. The Company's TAP technology uses tumor-targeting antibodies to deliver a highly potent, cell-killing agent specifically to cancer cells. Two ImmunoGen-developed TAP products have begun clinical evaluation: cantuzumab mertansine and huN901-DM1/BB-10901; the latter is licensed to British Biotech in certain territories.
